Phase 3 OCEANIC-STROKE trial shows asundexian cut recurrent ischemic stroke
Phase 3 OCEANIC-STROKE data showed asundexian plus antiplatelet therapy reduced recurrent ischemic stroke versus placebo. Major bleeding rates were similar between groups.
Intracranial Hemorrhage
DiseaseDisease Profile
Intracranial hemorrhage is bleeding within the skull, including intracerebral and subarachnoid hemorrhage, and can cause acute neurologic injury, raised intracranial pressure, and life-threatening complications.
- Category
- Diseases of the circulatory system
- Prevalence
- Hemorrhagic strokes account for about 13% of all strokes
- I62.9
Related News
Cogent Biosciences Prepares Up to Three FDA Filings for Bezuclastinib Following Pivotal Wins
Cogent Biosciences is preparing parallel FDA submissions for bezuclastinib across three indications following positive pivotal trial results, with potential launches beginning in late 2026 and full commercialization expected by early 2027.